Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Net Income Loss of -$4.31 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -121.5% in Net Income Loss from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $21.38 million | Q4 2014: $7.42 million | Q1 2015: -$6.35 million | Q2 2015: $4.73 million | Q3 2015: -$1.68 million | Q4 2015: -$12.23 million | Q1 2016: $8.50 million | Q2 2016: $1.10 million | Q3 2016: $4.24 million | Q4 2016: $1.67 million | Q1 2017: -$3.19 million | Q2 2017: -$2.17 million | Q3 2017: $1.82 million | Q4 2017: -$490.0 thousand | Q1 2018: -$2.83 million | Q2 2018: -$1.69 million | Q3 2018: -$2.58 million | Q4 2018: -$2.34 million | Q2 2019: $279.7 thousand | Q3 2019: -$1.60 million | Q4 2019: -$1.86 million | Q2 2020: $1.08 million | Q3 2020: $2.48 million | Q4 2020: $2.01 million | Q2 2021: $2.39 million | Q3 2021: $1.80 million | Q4 2021: $2.28 million | Q2 2022: $305.9 thousand | Q3 2022: $1.52 million | Q4 2022: $2.97 million | Q2 2023: $1.14 million | Q3 2023: $14.93 million | Q4 2023: $706.4 thousand | Q2 2024: $615.8 thousand | Q3 2024: -$11.04 million | Q4 2024: -$10.89 million | Q2 2025: -$5.88 million | Q3 2025: $13.70 million | Q4 2025: $18.59 million.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Net Income Loss has grown by 68.2%.
- Historical annual values: Fiscal year 2025: -$4.31 million | Fiscal year 2024: $20.11 million | Fiscal year 2023: $3.56 million | Fiscal year 2022: $8.90 million | Fiscal year 2021: $5.09 million | Fiscal year 2020: -$2.24 million | Fiscal year 2019: -$9.28 million | Fiscal year 2018: -$3.67 million | Fiscal year 2017: $3.81 million | Fiscal year 2016: -$683.0 thousand | Fiscal year 2015: $5.22 million | Fiscal year 2014: -$41.26 million | Fiscal year 2013: $1.49 million | Fiscal year 2012: -$15.06 million | Fiscal year 2011: -$13.58 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: